South Delhi Pharma, New Delhi, India

Jakafi (Ruxolitinib) tablets, for oral use

SDP are here to serve you through the quality pharmaceutical products as per your needs. Established in the year 1996, we have earned a global reputation in the market. Owing to superior quality widest range of Anti Cancer medicines.

Facts of Jakafi (Ruxolitinib)

Product: JAKAFI® (ruxolitinib) tablets, for oral use
Indication: bone marrow disorders (myelofibrosis, polycythemia vera).
Strength: Tablets: 5 mg, 10 mg, 15 mg, 20 mg and 25 mg.
Company: Incyte Corporation

South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Jakafi (Ruxolitinib) ” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Jakafi (Ruxolitinib) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Category:

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

3 + 11 =

What Jakafi is?

Jakafi is a kinase inhibitor indicated for treatment of:

  • intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis in adults.
  • polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea.
  • steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older.

What Ruxolitinib is?

Ruxolitinib (trade names Jakafi and Jakavi) is a drug for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, and for polycythemia vera (PCV) when there has been an inadequate response to or intolerance of hydroxyurea. Ruxolitinib has also been shown to improve cases of chronic graft versus host disease in patients following a bone marrow transplant.

Ruxolitinib is a janus kinase inhibitor (JAK inhibitor) with selectivity for subtypes JAK1 and JAK2. Ruxolitinib inhibits dysregulated JAK signaling associated with myelofibrosis. JAK1 and JAK2 recruit signal transducers and activators of transcription (STATs) to cytokine receptors leading to modulation of gene expression.

Reviews

There are no reviews yet.

Be the first to review “Jakafi (Ruxolitinib) tablets, for oral use”

Your email address will not be published. Required fields are marked *